However, several pro-inflammatory cytokines, including IL-1β, IL-6, and IL-17, are blocked by infliximab stimulation or combined treatment of infliximab and TNF-α, which indicates that anti-TNF-α treatment might modulate tumor-influenced inflammation in HCC [105]. Here, IL17A is linked to neoplasm.